Dogwood Therapeutics (DWTX) reported a net loss attributable to common stockholders of $11.5 million, or $0.34 per basic and diluted share, for the second quarter ended June 30, 2026. The company reported no revenue, compared with no revenue in the prior-year quarter.
Research and development expense rose to $3.2 million from $2.6 million, while general and administrative expense increased to $1.6 million from $1.3 million. The quarter included a $9.2 million non-cash IPR&D impairment charge, partially offset by a $2.5 million reduction in deferred tax liability expense.
- Cash on hand was $9.6 million as of June 30, 2026.
- Dogwood said its cash runway extends through the Halneuron Phase 2b readout expected in the fourth quarter of 2026.
- The Halneuron Phase 2b chemotherapy-induced neuropathic pain study had enrolled 217 patients, with top-line results expected in fall 2026.
- The company commenced a 12-week open-label Phase 2b long-term extension study for Halneuron.
- SP16 received FDA IND approval, with enrollment expected to begin in the second half of 2026 in a National Cancer Institute-funded study.
$DWTX Hedge Fund Activity
We have seen 8 institutional investors add shares of $DWTX stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC added 3,280,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $6,920,800
- BLACKROCK, INC. added 28,516 shares (+95053.3%) to their portfolio in Q2 2026, for an estimated $45,910
- NORTHERN TRUST CORP added 23,779 shares (+inf%) to their portfolio in Q1 2026, for an estimated $50,173
- GOLDMAN SACHS GROUP INC added 14,598 shares (+inf%) to their portfolio in Q1 2026, for an estimated $30,801
- BANK OF AMERICA CORP /DE/ removed 9,415 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $19,865
- GEODE CAPITAL MANAGEMENT, LLC added 8,864 shares (+11.2%) to their portfolio in Q2 2026, for an estimated $14,271
- UBS GROUP AG added 5,337 shares (+305.3%) to their portfolio in Q1 2026, for an estimated $11,261
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
